MALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targetingMALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting

NexEos Bio Announces FDA Clearance of IND Application to Proceed to Phase II/III Trial of NTX-1024 in Vernal Keratoconjunctivitis

2026/02/20 00:01
Okuma süresi: 3 dk

MALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting eosinophil-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared NexEos’s Investigational New Drug (IND) Application to proceed to a Phase II/III clinical trial of NTX-1024 for the treatment of patients with the rare disease, vernal keratoconjunctivitis (VKC). The planned Phase II/III trial is a single, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of NTX-1024 ophthalmic solution in patients with VKC.

This is on the heels of the positive results reported from an open-label, investigator-initiated study evaluating the efficacy, safety, and tolerability of NTX-1024 eye drops in adults with VKC. The study was conducted in Mexico and enrolled 15 patients with mild to moderate VKC who received NTX-1024 four times daily over a four-week period. Treatment led to significant improvement in patient-reported symptoms such as itching and quality of life, along with reductions in clinical signs of inflammation, including hyperemia and corneal fluorescein staining. NTX-1024 was also found to be safe and well-tolerated.

This marks the first clinical study to evaluate NTX-1024 in VKC, a rare and severe eosinophil-driven ocular condition that can lead to irreversible ocular damage, including vision loss, if left untreated. These results reinforce the therapeutic potential of NTX-1024 in VKC and have prompted NexEos to pursue further clinical development.

In addition, on January 16, 2026, the FDA granted Orphan Drug Designation to NTX-1024 for VKC.

“Clearance of our IND application, which included data from our open-label investigator-initiated study in Mexico, is an important and meaningful step for the program,” said Steve Tullman, CEO and Chairman of NexEos. “We are excited to advance clinical development of NTX-1024, which would be the first, ophthalmic therapeutic to neutralizes eosinophil cationic protein to reduce inflammation in rare forms of Allergic Conjunctivitis – Vernal Keratoconjunctivitis (VKC) and Atopic Keratoconjunctivitis (AKC). We are on track to initiate our Phase II/III clinical trial by the second half of this year, taking us closer to our objective of delivering a best-in-class therapeutic option to patients with VKC.”

About Vernal Keratoconjunctivitis (VKC)

VKC is a rare, chronic, and vision-threatening ocular inflammatory disease that is predominantly eosinophil-mediated. Activated eosinophils release toxic granule proteins, including eosinophil major basic protein-1 (eMBP1), resulting in damage to the ocular surface (Sacchetti, et al. 2021). VKC primarily affects children although approximately 10% of cases persist into adulthood (Di Zazzo A 2024). Uncontrolled VKC can result in severe ocular damage and permanent vision loss (Vichyanond, et al. 2014).

About NTX-1024 (gleceparin sodium)

NTX-1024 is a novel, topical ophthalmic solution targeting eosinophil cationic protein mediated inflammation in rare forms of allergic conjunctivitis, including VKC and AKC. NTX-1024 has completed proof of concept in VKC, received ODD approval, and now has FDA clearance of its IND application to advance to a Phase II/III clinical trial in VKC. NTX-1024 is the first therapeutic successfully targeting neutralization of eosinophil cationic proteins. Finally, NTX-1024 has the potential to be the first drug to be disease-modifying and steroid-sparing in VKC and AKC.

About NexEos Bio

NexEos Bio (www.nexeosbio.com) is a privately held medical diagnostics and therapeutics company based in Malvern, Pennsylvania, dedicated to improving the detection, diagnosis, treatment and life-long management of patients living with chronic, eosinophil-related inflammatory diseases. Through the licensing, development and commercialization of novel technologies, NexEos Bio is bringing new tools and therapies to market that address the unmet needs of patients suffering from eosinophil-related diseases.

Contacts

For more Information, please send inquiries to: [email protected]

Piyasa Fırsatı
NuNet Logosu
NuNet Fiyatı(NTX)
$0.0069
$0.0069$0.0069
+3.29%
USD
NuNet (NTX) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen [email protected] ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Forward Industries Bets Big on Solana With $4B Capital Plan

Forward Industries Bets Big on Solana With $4B Capital Plan

The firm has filed with the U.S. Securities and Exchange Commission to launch a $4 billion at-the-market (ATM) equity program, […] The post Forward Industries Bets Big on Solana With $4B Capital Plan appeared first on Coindoo.
Paylaş
Coindoo2025/09/18 04:15
Nvidia’s Strategic Masterstroke: Deepening Early-Stage Ties with India’s Booming AI Startup Ecosystem

Nvidia’s Strategic Masterstroke: Deepening Early-Stage Ties with India’s Booming AI Startup Ecosystem

BitcoinWorld Nvidia’s Strategic Masterstroke: Deepening Early-Stage Ties with India’s Booming AI Startup Ecosystem NEW DELHI, INDIA – October 2025: Nvidia Corporation
Paylaş
bitcoinworld2026/02/20 09:30
Bad Bunny Tops 2025 Latin Grammy With 12 Nominations, Ca7riel & Paco Amoroso Get 10

Bad Bunny Tops 2025 Latin Grammy With 12 Nominations, Ca7riel & Paco Amoroso Get 10

The post Bad Bunny Tops 2025 Latin Grammy With 12 Nominations, Ca7riel & Paco Amoroso Get 10 appeared on BitcoinEthereumNews.com. Bad Bunny and Ca7riel & Paco Amoroso among the most nominated artists for the 2025 Latin Grammys. Mike Coppola/MG25/Getty Images for The Met Museum/Vogue, Dana Jacobs/WireImage Puerto Rican megastar Bad Bunny leads the 26th Annual Latin Grammy Awards with the most nominations, followed closely by breakout Argentinian experimental trap, hip-hop and pop duo Ca7riel & Paco Amoroso, and prolific music producer Edgar Barrera, who once again ranks among the year’s top nominees. Bad Bunny earned 12 nominations, including Album of the Year for Debí Tirar Más Fotos, Record and Song of the Year for “Baile Inolvidable” and “DtMF​.”​ Songs from his hit album even compete against each other in three categories. Ca7riel & Paco Amoroso received 10 nominations, including Album of the Year for Papota and Record and Song of the Year for “El Día del Amigo” and “#Tetas.” The duo gained widespread popularity following their 2024 NPR Tiny Desk Concert​, which has garnered more than 42 million views to date.​ Five of their nine album tracks are from that performance​. Sought-after music producer Edgar Barrera also secured 10 nominations​ —​ one more than in 2024​ —​ including Songwriter and Producer of the Year. He received additional recognition for his contributions to songs across urban, tropical and regional categories, including Maluma’s “Cosas Pendientes,” Karol G’s “Si Antes Te Hubiera Conocido” and Grupo Frontera’s “Hecha Pa’ Mí.” Other top nominees include Natalia Lafourcade with eight nominations, Liniker with six, and Alejandro Sanz with four. Also in the mix are Rauw Alejandro, Gloria Estefan, Shakira and Rubén Blades. In announcing the nominees, Manuel Abud, CEO of The Latin Recording Academy, highlighted Latin music’s expanding influence. “The impact of Latin music continues to grow on a global level, and all of the nominated artists encompass its diversity and richness while continuing to preserve…
Paylaş
BitcoinEthereumNews2025/09/18 06:41